TransCode Therapeutics AI Stock Analysis
Want to see RNAZ full AI Analyst Report?
TransCode Therapeutics (RNAZ) AI Stock Analysis
TransCode Therapeutics
(NASDAQ:RNAZ)
The score is primarily constrained by weak financial performance (no revenue, widening losses, and ongoing cash burn), with limited valuation support due to continued losses. Offsetting factors include constructive near-term technical momentum and positive corporate developments around the pipeline and planned Phase 2a work, though high volatility and stretched oscillators temper the technical contribution.
TransCode Therapeutics (RNAZ) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.48M
- Dividend Yield
- ―
- Average Volume (3M)
- 54.05K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 2.76
- Revenue Growth
- ―
- EPS Growth
- 86.74%
- Country
- US
- Employees
- 12
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
TransCode Therapeutics Business Overview & Revenue Model
Company Description
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead ther...
How the Company Makes Money
null
TransCode Therapeutics Financial Statement Overview
Summary
Very weak operating profile with no revenue, widening net losses through TTM, and persistent negative operating/free cash flow indicating ongoing funding dependence. Low debt helps near-term solvency, but equity volatility (including periods of negative equity) and continued cash burn are major risks.
Income Statement
12Very NegativeBalance Sheet
48NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -52.65K | 0 | -534.86K | -516.75K | -98.61K | -42.47K |
| EBITDA | -42.30M | -34.31M | -16.19M | -17.97M | -17.47M | -6.71M |
| Net Income | -42.78M | -34.66M | -16.75M | -18.55M | -17.56M | -6.84M |
Balance Sheet | ||||||
| Total Assets | 151.01M | 162.40M | 7.29M | 5.17M | 7.59M | 22.94M |
| Cash, Cash Equivalents and Short-Term Investments | 8.38M | 17.81M | 5.81M | 2.77M | 4.97M | 20.83M |
| Total Debt | 652.41K | 0 | 38.29K | 450.57K | 0 | 0 |
| Total Liabilities | 12.65M | 152.06M | 9.31M | 3.53M | 4.35M | 2.53M |
| Stockholders Equity | 138.36M | 10.34M | -2.02M | 1.64M | 3.24M | 20.40M |
Cash Flow | ||||||
| Free Cash Flow | -22.61M | -19.52M | -13.36M | -18.11M | -15.86M | -5.52M |
| Operating Cash Flow | -22.61M | -19.52M | -13.34M | -18.07M | -15.76M | -5.27M |
| Investing Cash Flow | -4,436 | -4,436 | -21.76K | -35.61K | -100.92K | -251.82K |
| Financing Cash Flow | 23.62M | 31.52M | 16.40M | 15.91M | 5,989 | 25.52M |
TransCode Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNAZ, the sentiment is Negative. The current price of 1.40 is below the 20-day moving average (MA) of 1.63, below the 50-day MA of 1.70, and below the 200-day MA of 5.81, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 35.07 is Neutral, neither overbought nor oversold. The STOCH value of 12.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNAZ.
TransCode Therapeutics Risk Analysis
TransCode Therapeutics disclosed 98 risk factors in its most recent earnings report. TransCode Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksTransCode Therapeutics Peers Comparison
Overall Rating
- RNAZ49Neutral
KPRX41Neutral
LYRA41Neutral
INAB39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| RNAZ | 49Neutral | $22.86M | -0.03 | -58.08% | ― | ― | 86.74% |
| KPRX | 41Neutral | $6.11M | -0.54 | -63.39% | ― | ― | 19.38% |
| LYRA | 41Neutral | $337.23K | -0.01 | 455.31% | ― | -74.05% | 73.08% |
| INAB | 39Underperform | $9.73M | -0.69 | -93.66% | ― | ― | 81.16% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RNAZ | Transcode Therapeutics, Inc. | 1.40 | -7.02 | -83.37% | |
| KPRX | Kiora Pharmaceuticals, Inc. | 1.35 | -0.85 | -38.64% | |
| LYRA | Lyra Therapeutics, Inc. | 0.19 | -3.63 | -95.03% | |
| INAB | In8bio, Inc. | 0.87 | -0.77 | -46.89% |
TransCode Therapeutics Corporate Events
TransCode Therapeutics Shareholders Approve Key Capital Measures
PositiveOn July 20, 2026, TransCode Therapeutics held its 2026 Annual Meeting of Stockholders, where 52.1% of the company’s voting power was represented, constituting a quorum for business. All proposals presented were approved, reinforcing the company’s cap...
TransCode Therapeutics Updates Preferred Stock Ownership Limits
PositiveOn July 16, 2026, TransCode Therapeutics, Inc. amended and restated the certificate of designation governing its Series C Non-Voting Convertible Preferred Stock, following consent from a majority of Series C holders and approval by its board. The ame...
TransCode Adjourns Annual Meeting Amid Nasdaq Listing Steps
NeutralOn July 2, 2026, TransCode Therapeutics opened its 2026 Annual Meeting of Stockholders but adjourned it to July 20, 2026, after preliminary results showed all proposals had sufficient support for approval. The postponement was driven by administrativ...
TransCode Highlights Progress of Lead RNA Cancer Therapeutic
PositiveOn June 18, 2026, TransCode Therapeutics posted an investor presentation outlining its progress across three cancer treatment platforms and highlighting its lead RNA therapeutic candidate, TTX-MC138. The Phase 2a-stage antagomiR targets microRNA-10b...
TransCode Therapeutics Advances TTX-MC138 After Positive Phase 1a
PositiveOn June 3, 2026, TransCode Therapeutics reported that its Phase 1a dose-escalation trial of lead RNA-based cancer therapeutic TTX-MC138 met its primary safety endpoint with no dose-limiting toxicities in 16 metastatic cancer patients given 86 total d...
TransCode Sets Key Deadlines for 2026 Shareholder Meeting
NeutralTransCode Therapeutics said it plans to hold its 2026 annual meeting of stockholders on July 2, 2026, with May 28, 2026, set as the record date for shareholders entitled to notice and voting. The company noted that its 2025 annual meeting occurred on...
TransCode Therapeutics Receives Nasdaq Listing Deficiency Notice
NegativeOn May 19, 2026, TransCode Therapeutics disclosed that it received a deficiency letter from Nasdaq after reporting stockholders’ equity of about $1.25 million as of March 31, 2026, below the $2.5 million minimum required for continued listing on the...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 24, 2026